The KCNQ/KV7 potassium channel opener Retigabine as add-on therapy for partial epilepsy. Pharmacological and clinical data

被引：0
|
作者：
Orhan, Goekce [1 ]
Wuttke, Thomas V. [2 ,3 ,4 ,5 ]
Nies, Anne T. [6 ]
Schwab, Matthias [6 ,7 ]
Lerche, Holger [1 ]
机构：
[1] Univ Tubingen, Hertie Inst Klin Hirnforsch, Abt Neurol Schwerpunkt Epileptol, D-72076 Tubingen, Germany
[2] Harvard Univ, Sch Med, Dept Neurosurg, MGH HMS Ctr Nervous Syst Repair, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Dept Neurol, MGH HMS Ctr Nervous Syst Repair, Boston, MA 02114 USA
[4] Harvard Univ, Program Neurosci, Sch Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Nayef Al Rodhan Labs, Boston, MA 02114 USA
[6] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[7] Univ Klinikum Tubingen, Klin Pharmakol Abt, Inst Expt & Klin Pharmakol & Toxikol, D-72076 Tubingen, Germany
来源：
PSYCHOPHARMAKOTHERAPIE | 2011年 / 18卷 / 04期
关键词：
Epilepsy; potassium channel; pharmacotherapy; antiepileptic drug; retigabine; ANTICONVULSANT RETIGABINE; PHARMACOKINETIC INTERACTION; DIFFERENT PATTERNS; N-GLUCURONIDATION; HUMAN LIVER; D-23129; ACTIVATION; MODEL; CURRENTS; BINDING;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The KCNQ/K(V)7 potassium channel opener Retigabine as add-on therapy for partial epilepsy. Pharmacological and clinical data This review summarizes the pharmacological, preclinical and clinical data on the new anticonvulsant compound retigabine (RGB) and discusses the impact of this drug for patients with refractory partial epilepsy. Retigabine increases the activity of voltage-gated KCNQ/K(V)7 channels and thus exhibits a novel mechanism of action as compared to available anticonvulsive drugs. Retigabine has been investigated in three multicenter, randomized, double-blind and placebo-controlled clinical phase 11 and III trials in adults with >= 4 partialonset seizures per month and showed efficacy in pharmacoresistant epilepsy. In march 2011, Retigabine received approval in Europe as Trobalt (R).
引用
收藏
页码：148 / +
页数：8
相关论文
共 43 条
  • [1] Retigabine/Ezogabine, a KCNQ/KV7 channel opener: pharmacological and clinical data
    Orhan, Goekce
    Wuttke, Thomas V.
    Nies, Anne T.
    Schwab, Matthias
    Lerche, Holger
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (12) : 1807 - 1816
  • [2] Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy
    Zahra, Aqeela
    Liu, Ru
    Wang, Jingjing
    Wu, Jianping
    NEUROLOGICAL SCIENCES, 2023, 44 (11) : 3819 - 3825
  • [3] Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy
    Aqeela Zahra
    Ru Liu
    Jingjing Wang
    Jianping Wu
    Neurological Sciences, 2023, 44 : 3819 - 3825
  • [4] Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats
    Sander, S. E.
    Lemm, C.
    Lange, N.
    Hamann, M.
    Richter, A.
    NEUROPHARMACOLOGY, 2012, 62 (02) : 1052 - 1061
  • [5] Discovery of a novel Kv7 channel opener as a treatment for epilepsy
    Davoren, Jennifer E.
    Claffey, Michelle M.
    Snow, Sheri L.
    Reese, Matthew R.
    Arora, Gaurav
    Butler, Christopher R.
    Boscoe, Brian P.
    Chenard, Lois
    DeNinno, Shari L.
    Drozda, Susan E.
    Duplantier, Allen J.
    Moine, Ludivine
    Rogers, Bruce N.
    Rong, SuoBao
    Schuyten, Katherine
    Wright, Ann S.
    Zhang, Lei
    Serpa, Kevin A.
    Weber, Mark L.
    Stolyar, Polina
    Whisman, Tammy L.
    Baker, Karen
    Tse, Karen
    Clark, Alan J.
    Rong, Haojing
    Mather, Robert J.
    Lowe, John A., III
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (21) : 4941 - 4944
  • [6] Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine
    Schenzer, A
    Friedrich, T
    Pusch, M
    Saftig, P
    Jentsch, TJ
    Grötzinger, J
    Schwake, M
    JOURNAL OF NEUROSCIENCE, 2005, 25 (20): : 5051 - 5060
  • [7] Kv7 channel opener retigabine reduces self-administration of cocaine but not sucrose in rats
    Urena, Esteban S.
    Diezel, Cody C.
    Serna, Mauricio
    Halaufia, Grace
    Majuta, Lisa
    Barber, Kara R.
    Vanderah, Todd W.
    Riegel, Arthur C.
    ADDICTION BIOLOGY, 2024, 29 (08)
  • [8] The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats
    Knapp, Clifford M.
    O'Malley, Matthew
    Datta, Subimal
    Ciraulo, Domenic A.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2014, 40 (03): : 244 - 250
  • [9] Preliminary report of use of topiramate as add-on therapy in refractory partial epilepsy.
    Fels, A
    Pagliuca, M
    Simonelli, V
    Ronga, B
    Andreone, V
    EPILEPSIA, 1999, 40 : 250 - 250
  • [10] Gabapentin as add-on therapy in patients with refractory symptomatic/cryptogenetic partial epilepsy.
    Volpi, L
    Bisulli, F
    d'Orsi, G
    Zaniboni, A
    Bisulli, A
    Testoni, S
    Tonon, C
    Pantieri, R
    Michelucci, R
    Rubboli, G
    Tassinari, CA
    EPILEPSIA, 1999, 40 : 69 - 69
12345